The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.

Abstract

Acrodermatitis continua of Hallopeau is a rare subtype of pustular psoriasis that presents as a sterile, pustular eruption commonly in the finger tips and toes. This disease inflicts both the skin and nail bed, and causes severe disfigurement of the distal phalanges. Because it is a variant of pustular psoriasis, acrodermatitis continua of Hallopeau is commonly managed with antipsoriatic medications. Common approaches to treatment include topical therapy (corticosteroids, vitamin D analogs, and calcineurin inhibitors), systemic therapy, and in more severe cases, biologic therapy. This review will discuss how acrodermatitis continua of Hallopeau is diagnosed and how it is managed, with a particular emphasis on the use of biologics.

• Authors: Khalad Maliyar, Erika L Crowley, Fabian Rodriguez-Bolanos, Ashley O'Toole, Melinda J Gooderham
• Journal: Journal of cutaneous medicine and surgery (J Cutan Med Surg) 2019 Jul/Aug Vol. 23 Issue 4 Pg. 428-435 ISSN: 1615-7109 [Electronic] United States
• PMID: 30938189 (Publication Type: Journal Article, Review)

Chemical References

• Biological Products
• Dermatologic Agents
• Interleukin-1
• Interleukin-17
• Interleukin-23
• Tumor Necrosis Factor-alpha

Topics

• Acrodermatitis (diagnosis, drug therapy)
• Biological Products (therapeutic use)
• Dermatologic Agents (therapeutic use)
• Humans
• Interleukin-1 (antagonists & inhibitors)
• Interleukin-17 (antagonists & inhibitors)
• Interleukin-23 (antagonists & inhibitors)
• Psoriasis (diagnosis, drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)